

Japan's Otsuka Pharma enters into \$30 M investment contract with AN Venture Partners

01 March 2024 | News

To create global biotech companies that leverage science from Japan

Japan headquartered Otsuka Pharmaceutical Co. has concluded an investment contract of \$30 million with AN Venture Partners (ANV), a global capital fund aiming to create global biotech companies that leverage science from Japan.

ANV was established by individuals with extensive experience in startup and investment activities at Japanese and American venture capital firms. ANV primarily sources innovative science seeds from Japan and focuses on nurturing them into global biotechnology companies. Japan Investment Corporation and several private companies are currently investing in ANV as limited liability partners.

Through investment in the first fund operated by ANV, Otsuka will contribute to maximise the corporate value of Japanese science innovation by establishing companies in the United States, which is the largest biotech ecosystem in the world.

Otsuka will be able to receive dividends from investment profits and gain investment opportunities in the latest innovations. By dispatching personnel to ANV, Otsuka will also deepen its know-how in the exploration and nurturing of new sciences. Otsuka can also build on its existing strengths in drug discovery and original innovation through "horizontal collaborations" which integrate the technologies and insights of global academia and bio-ventures.